Lumicera Health Services Selected as Part of the Limited Specialty Pharmacy Network for MAVENCLAD®

Lumicera Health Services, a leading specialty pharmacy and services company, announced that EMD Serono has selected it as part of the limited specialty network for MAVENCLAD (cladribine), a prescription medicine used to treat relapsing forms of multiple sclerosis (MS). For more information about MAVENCLAD, go to

Relapsing Multiple Sclerosis, also referred to as flare-ups or exacerbations, can occur as a new symptom or a worsening of existing symptoms within patients who have MS. Relapsing MS is considered an autoimmune disease—instead of defending the body against viruses or bacteria, the immune system attacks the body itself. Symptoms can last from days to months and cause permanent damage, potentially leading to future disabilities. Access to MAVENCLAD will provide additional options for MS patients who previously had a poor response to therapy.

“We are proud to be selected as part of the limited specialty network for MAVENCLAD,” said Sharon Faust, Lumicera’s Senior Vice President of Specialty Pharmacy. “Receiving access to MAVENCLAD demonstrates Lumicera’s expertise and dedication to caring for patients with Neurologic conditions and we are excited to form this strong partnership with EMD Serono”

About Lumicera Health Services
Lumicera offers innovative specialty pharmacy solutions, framed in the core principles of transparency and stewardship. Lumicera is defining the “new norm” in specialty pharmacy to optimize patient well-being and is dedicated to improving specialty pharmacy care, one patient at a time, through educational, clinical, financial and service excellence.